TNGX

+ Watchlist + Portfolio

Tango Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.45
52-Week Range: $6.69 – $34.39
Market Cap: $3.92B
P/E (TTM): —
EPS (TTM): -0.85
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.82
PEG Ratio: —
Return on Equity: -21.34%
Return on Assets: -12.99%
Gross Margin: -148.37%
Operating Margin: -253.38%
Profit Margin: -229.92%
Current Ratio: 50.82
Debt/Equity: 0.03
Total Debt: $31.99M
Free Cash Flow: $-71.87M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.94B

TNGX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$24.86M	$36.53M	$42.07M	$62.38M
Research & Development	$105.91M	$115.20M	$143.92M	$132.16M
Selling, General & Admin	$30.02M	$35.50M	$43.75M	$41.51M
Operating Expenses	$135.93M	$150.70M	$187.66M	$173.67M
Operating Income	-$111.07M	-$114.17M	-$145.59M	-$111.29M
EBITDA	-$109.46M	-$111.76M	-$143.10M	-$109.01M
Pretax Income	-$108.12M	-$101.61M	-$130.09M	-$101.59M
Income Tax	$54.00K	$134.00K	$208.00K	$4.00K
Net Income	-$108.18M	-$101.74M	-$130.30M	-$101.59M
Diluted EPS	-1.23	-1.08	-1.19	-0.87
Diluted Shares	87.82M	94.57M	109.23M	116.17M

TNGX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$59.97M	$66.39M	$69.53M	$112.28M
Receivables	$2.00M	$0.00	—	—
Current Assets	$375.27M	$346.54M	$266.34M	$353.76M
Total Assets	$436.47M	$402.57M	$316.49M	$398.69M
Current Liabilities	$55.55M	$45.94M	$38.17M	$21.68M
Total Debt	$41.13M	$38.92M	$36.49M	$33.57M
Total Liabilities	$186.99M	$149.46M	$116.97M	$52.51M
Retained Earnings	-$269.51M	-$371.26M	-$501.56M	-$603.15M
Shareholders' Equity	$249.48M	$253.11M	$199.52M	$346.18M
Working Capital	$319.73M	$300.60M	$228.17M	$332.08M

TNGX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$109.08M	-$117.98M	-$131.50M	-$138.89M
Capital Expenditure	-$7.69M	-$1.53M	-$754.00K	-$1.05M
Free Cash Flow	-$116.77M	-$119.51M	-$132.25M	-$139.93M
Depreciation & Amortisation	$1.61M	$2.42M	$2.50M	$2.28M
Stock-Based Compensation	$14.23M	$19.08M	$28.90M	$26.43M
Investing Cash Flow	$26.40M	$41.43M	$86.13M	-$40.87M
Financing Cash Flow	$1.61M	$82.41M	$47.66M	$222.50M
Net Change in Cash	-$81.07M	$5.85M	$2.29M	$42.75M

TNGX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$5.39M	$3.18M	$53.81M	$0.00	$0.00	$0.00
Research & Development	$36.44M	$32.81M	$30.82M	$32.10M	$33.53M	$37.20M
Selling, General & Admin	$11.48M	$11.34M	$8.92M	$9.76M	$15.23M	$22.59M
Operating Expenses	$47.92M	$44.15M	$39.74M	$41.86M	$48.77M	$59.78M
Operating Income	-$42.53M	-$40.97M	$14.07M	-$41.86M	-$48.77M	-$59.78M
EBITDA	-$41.91M	-$40.34M	$14.63M	-$41.38M	-$48.31M	-$59.36M
Pretax Income	-$39.84M	-$38.82M	$15.87M	-$38.80M	-$45.51M	-$55.34M
Income Tax	$34.00K	$35.00K	-$10.00K	-$55.00K	$1.00K	$1.00K
Net Income	-$39.88M	-$38.85M	$15.88M	-$38.75M	-$45.51M	-$55.34M
Diluted EPS	-0.36	-0.35	0.13	-0.29	-0.32	-0.37
Diluted Shares	110.30M	110.54M	117.78M	131.59M	143.58M	149.88M

TNGX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$58.43M	$39.27M	$58.34M	$112.28M	$157.83M	$345.56M
Current Assets	$224.93M	$190.10M	$163.78M	$353.76M	$392.33M	$1.03B
Total Assets	$274.31M	$237.89M	$210.14M	$398.69M	$435.79M	$1.07B
Current Liabilities	$35.92M	$40.02M	$18.44M	$21.68M	$14.33M	$20.30M
Total Debt	$36.95M	$35.01M	$34.76M	$33.57M	$32.79M	$31.99M
Total Liabilities	$107.55M	$102.94M	$50.10M	$52.51M	$44.29M	$49.35M
Retained Earnings	-$541.43M	-$580.29M	-$564.40M	-$603.15M	-$648.67M	-$704.01M
Shareholders' Equity	$166.76M	$134.95M	$160.03M	$346.18M	$391.51M	$1.02B
Working Capital	$189.01M	$150.07M	$145.34M	$332.08M	$378.00M	$1.01B

TNGX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$41.70M	-$36.52M	-$30.95M	-$29.72M	-$44.36M	-$38.87M
Capital Expenditure	-$51.00K	-$624.00K	-$151.00K	-$222.00K	—	—
Free Cash Flow	-$41.75M	-$37.14M	-$31.10M	-$29.94M	-$44.36M	-$38.87M
Depreciation & Amortisation	$622.00K	$625.00K	$555.00K	$479.00K	$463.00K	$425.00K
Stock-Based Compensation	$7.25M	$6.57M	$6.63M	$5.98M	$10.80M	$16.89M
Investing Cash Flow	$30.60M	$16.78M	$47.48M	-$135.72M	$9.63M	-$445.97M
Financing Cash Flow	$2.00K	$581.00K	$2.54M	$219.38M	$79.85M	$672.57M
Net Change in Cash	-$11.10M	-$19.16M	$19.07M	$53.94M	$45.12M	$187.73M

Market Snapshot

About

Tango Therapeutics is a biotechnology company developing precision oncology therapies that target cancer vulnerabilities to deliver durable clinical benefit. The company focuses on synthetic lethality and tumor immunology approaches, creating treatments designed to exploit specific genetic alterations in cancer cells. Tango utilizes its proprietary discovery platform to identify novel drug targets and advance clinical-stage programs.